Acute myeloid leukemia trials in Germany

In Germany 44 Also abroad 761

44 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
Where
Tübingen
Age
18 years and over
People
20
Run by
University Hospital Tuebingen
See details and how to joinNCT06252584
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Berlin, Munich, Ulm
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Aachen, Berlin, Bochum, Bonn, Bremen, Brunswick, Chemnitz, Dortmund, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Greifswald, Halle (Saale), Hamburg, Hanover, Heidelberg, Heilbronn, Homburg, Jena, Karlsruhe, Ludwigshafen Am Rhein, Magdeburg, Mainz, Marburg, Minden, Munich, Nuremberg, Oldenburg, Passau, Regensburg, Rostock, Stuttgart, Ulm, Wuppertal
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 1Taking people
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Where
Berlin, Munich
Age
18 years and over
People
40 worldwide
Run by
Charm Therapeutics
See details and how to joinNCT07751991 · EU 2026-526409-14-00
Phase 3Taking people
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Where
Arnsberg, Aschaffenburg, Bad Saarow, Berlin, Bochum, Bonn, Bremen, Brunswick, Darmstadt, Dortmund, Frankfurt Am Main, Giessen, Goch, Greifswald, Halle (Saale), Hamburg, Hamm, Hannover, Hanover, Heilbronn, Herne, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Ludwigshafen Am Rhein, Magdeburg, Mainz, Minden, Munich, Offenburg, Oldenburg, Regensburg, Rostock, Stuttgart, Traunstein, Trier, Tuebingen, Ulm, Villingen-Schwenningen, Wuppertal
Age
18 years to 75 years
People
650 worldwide
Run by
University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel, Leipzig, München, Würzburg
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 3Taking people
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Where
Freiburg im Breisgau, Halle, Jena, Leipzig, Munich
Age
18 years to 75 years
People
366 worldwide
Run by
Priothera SAS
See details and how to joinNCT05429632
No phaseTaking people
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Where
Aachen, Greifswald, Halle, Rostock
Age
6 years and over
People
4,000 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024
Phase 3Taking people
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Where
Aachen, Greifswald, Halle (Saale), Halle Saale, Rostock, Zwickau
Age
18 years and over
People
339 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06713837 · EU 2024-514517-35-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Dresden, Frankfurt Am Main, Halle (Saale), Heidelberg, Munich, Ulm
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Berlin, Bochum, Bonn, Bremen, Brunswick, Flensburg, Freiburg im Breisgau, Halle Saale, Hamburg, Hanover, Heilbronn, Homburg, Karlsruhe, Mainz, Minden, Munich, Oldenburg, Regensburg, Stuttgart, Tuebingen, Ulm
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Brunswick, Chemnitz, Duesseldorf, Hamburg, Heidelberg, Herne, Jena, Leipzig, Minden, Stuttgart, Tuebingen
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Aachen, Bad Saarow, Berlin, Cottbus, Frankfurt Am Main, Halle Saale, Homburg, Leipzig, Mainz, Muenster, Munich
Age
18 years and over
People
1,300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Hamburg, Leipzig, Mainz, Ulm
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Brunswick, Freiburg im Breisgau, Halle Saale, Heidelberg
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 1Taking people
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
Where
Berlin, Dresden, Essen, Frankfurt Am Main, Hamburg, Hanover, Heidelberg, Marburg, Munich, Ulm, Wuerzburg
Age
18 years and over
People
37 worldwide
Run by
AvenCell Europe GmbH
See details and how to joinNCT05949125 · EU 2022-501797-19-00
Phase 1/2Taking people
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Where
Aachen, Cologne, Duesseldorf, Frankfurt Am Main, Jena, Munich
Age
18 years and over
People
38
Run by
Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05807932 · EU 2024-514688-24-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Aachen, Freiburg im Breisgau, Lübeck, Mannheim
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Leipzig, Ulm
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Berlin, Bochum, Bonn, Bremen, Brunswick, Darmstadt, Essen, Flensburg, Freiburg im Breisgau, Greifswald, Halle (Saale), Hamburg, Hanover, Heilbronn, Herne, Homburg, Karlsruhe, Magdeburg, Mainz, Minden, Munich, Oldenburg, Potsdam, Regensburg, Stuttgart, Tuebingen, Ulm, Wuppertal
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
Phase 2Taking people
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Where
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald, Halle, Jena, Kiel, Leipzig, Mainz, Münster, Nuremberg, Rostock, Stuttgart
Age
18 years and over
People
220
Run by
Technische Universität Dresden
See details and how to joinNCT07025824
Phase 2Taking people
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
Where
Aachen, Augsburg, Bamberg, Bielefeld, Chemnitz, Cologne, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Halle (Saale), Heidelberg, Hildesheim, Kiel, Leipzig, Mannheim, Marburg, Muenster, Munich, Nuremberg, Regensburg, Stuttgart, Wiesbaden
Age
18 years to 70 years
People
146
Run by
Technische Universität Dresden
See details and how to joinNCT05904106 · EU 2024-515267-59-00
Phase 2Taking people
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
Where
Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mainz, Mannheim, Muenster, Munich, Oldenburg, Rostock, Ulm
Age
18 years to 75 years
People
76
Run by
Technische Universität Dresden
See details and how to joinNCT06717958 · EU 2023-509055-14-00
Phase 1Taking people
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Where
Hanover
Age
18 years and over
People
171 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT06001788 · EU 2023-510288-37-00